We are live on
!
Find out more
Westfield Capital Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
49.45%
This Fund
S&P 500
This Quarter
Est. Return
+10.11%
1 Year Est. Return
+49.45%
3 Year Est. Return
+148.08%
5 Year Est. Return
+180.9%
10 Year Est. Return
+972.69%
AUM
$16.8B
AUM Growth
+$245M
(+1.5%)
Cap. Flow
-$838M
Cap. Flow
% of AUM
-4.98%
Top 10 Holdings %
Top 10 Hldgs %
24.01%
Holding
277
New
42
Increased
50
Reduced
131
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$87.8M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$78.8M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$77.7M |
| 4 |
WillScot Mobile Mini Holdings
WSC
|
+$74.7M |
| 5 |
S&P Global
SPGI
|
+$70.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLRN
Acceleron Pharma
XLRN
|
+$154M |
| 2 |
PayPal
PYPL
|
+$120M |
| 3 |
Synchrony
SYF
|
+$101M |
| 4 |
Mercado Libre
MELI
|
+$94.1M |
| 5 |
Chipotle Mexican Grill
CMG
|
+$91.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.86% |
| 2 | Healthcare | 17.79% |
| 3 | Industrials | 14.72% |
| 4 | Consumer Discretionary | 11.56% |
| 5 | Financials | 9.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
ConocoPhillips
COP
$141B
| $76.6M | 0.46% |
1,060,590
-209,214
| -16% | -$15.2M |
|
|
SBNY
77
DELISTED
Signature Bank
SBNY
| $76.4M | 0.45% |
236,227
+6,155
| +3% | +$1.92M |
|
78
Quest Diagnostics
DGX
$26.3B
| $76.1M | 0.45% |
439,902
+51,505
| +13% | +$7.84M |
|
79
Ulta Beauty
ULTA
$24.3B
| $75.9M | 0.45% |
184,160
-5,070
| -3% | -$1.97M |
|
|
CTLT
80
DELISTED
CATALENT, INC.
CTLT
| $75.4M | 0.45% |
588,819
-5,948
| -1% | -$764K |
|
|
81
S&P Global
SPGI
$120B
| $75.2M | 0.45% |
159,349
+155,075
| +3,628% | +$70.9M |
|
82
Marriott International
MAR
$92.3B
| $72.6M | 0.43% |
+439,615
| New | +$69.2M |
|
83
Brookfield
BN
$108B
| $69.1M | 0.41% |
+2,124,095
| New | +$67.2M |
|
|
XLNX
84
DELISTED
Xilinx Inc
XLNX
| $68.7M | 0.41% |
324,179
-106,641
| -25% | -$21M |
|
85
Haemonetics
HAE
$4B
| $68.3M | 0.41% |
1,287,677
-68,937
| -5% | -$4.2M |
|
86
ITT
ITT
$19.1B
| $67.5M | 0.4% |
660,667
-63,286
| -9% | -$6.19M |
|
|
SRC
87
DELISTED
SPIRIT REALTY CAPITAL, INC.
SRC
| $66.8M | 0.4% |
1,386,287
-916
| -0.1% | -$43.6K |
|
88
Essex Property Trust
ESS
$18.5B
| $66.7M | 0.4% |
189,416
-5,560
| -3% | -$1.89M |
|
89
Option Care Health
OPCH
$3.56B
| $65.9M | 0.39% |
2,316,543
+149,344
| +7% | +$3.92M |
|
90
Pacira BioSciences
PCRX
$997M
| $65.8M | 0.39% |
1,093,482
-32,837
| -3% | -$1.81M |
|
91
Axalta
AXTA
$8.17B
| $64.7M | 0.38% |
1,953,316
-153,423
| -7% | -$4.87M |
|
92
F5
FFIV
$22.7B
| $64.2M | 0.38% |
262,482
-70,187
| -21% | -$15.6M |
|
93
Innoviva
INVA
$1.48B
| $63.5M | 0.38% |
3,683,485
+186,640
| +5% | +$3.18M |
|
|
WCC
94
WESCO International
WCC
$17.7B
| $63.3M | 0.38% |
+481,297
| New | +$61.5M |
|
|
SCHW
95
Charles Schwab
SCHW
$187B
| $61.2M | 0.36% |
+727,951
| New | +$58.9M |
|
96
Neurocrine Biosciences
NBIX
$16.6B
| $60.1M | 0.36% |
706,226
-16,952
| -2% | -$1.56M |
|
97
Williams-Sonoma
WSM
$29.6B
| $58.9M | 0.35% |
696,504
-228
| -0% | -$21.2K |
|
98
Gartner
IT
$11.7B
| $58.7M | 0.35% |
175,635
-47,001
| -21% | -$15.1M |
|
99
Elanco Animal Health
ELAN
$11.1B
| $58.7M | 0.35% |
+2,068,021
| New | +$64.3M |
|
100
Celanese
CE
$4.82B
| $58.3M | 0.35% |
347,133
-4,794
| -1% | -$781K |
|
Similar funds
OAG
JG
CHP
SC
Westfield Capital Management's Q4 2021 Portfolio in Review
As of Q4 2021, Westfield Capital Management held 277 positions worth $16.8B, up 1.5% from $16.6B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Westfield Capital Management withdrew a net $838M in Q4 2021, closing 33 positions and reducing 131 holdings. Its most notable exit was Acceleron Pharma, an estimated $154M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Westfield Capital Management opened a new position in Tesla worth $92.2M.
- Westfield Capital Management's largest Q4 2021 buy was Tesla: 261,813 shares worth $92.2M.
- Westfield Capital Management added most to Ascendis Pharma A/S in Q4 2021, an estimated $78.8M increase.
- Westfield Capital Management's biggest Q4 2021 reduction was PayPal, cutting an estimated $120M.
- Westfield Capital Management fully exited Acceleron Pharma in Q4 2021, selling an estimated $154M.
- Westfield Capital Management's ten largest holdings make up 24% of its $16.8B portfolio in Q4 2021.
- Westfield Capital Management opened 42 new positions and closed 33 in Q4 2021.
- Westfield Capital Management's portfolio value rose 1.5% quarter-over-quarter to $16.8B.
Based on Westfield Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.